Vertex Pharmaceuticals Incorporated VRTX NDXSPXR3KPHARMA
Company Overview
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Why Investors Should Care
Generates a return on equity of 23.5%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 20.9%.
Revenue has grown at a 10.4% CAGR over the past five years.
Maintains a net profit margin of 35.0%.
Carries low leverage with a debt-to-equity ratio of 0.10.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $12.00B (+8.9% YoY); net profit $3.95B.
- Trailing 12 Months Year-on-year growth — revenue +12.5%, earnings +8.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 10.4%, profit CAGR 6.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 10.35% |
| 1 Year: | 12.50% |
Compounded Profit Growth
| 5 Years: | 5.97% |
| 1 Year: | 8.00% |
Stock Price Performance
| 1 Year: | +37.94% |
| 6 Months: | +19.58% |
| 3 Months: | +22.22% |
| 1 Month: | +12.83% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)59.36 · Neutral
P/E of 31.79 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 23.5%.
- Healthy ROCE of 20.9%.
- Excellent profit margin of 35.0%.
- Compounding revenue at 10.4% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VRTX Vertex Pharmaceuticals Incorporated NDXSPXR3KPHARMA | 546.12 | 31.79 | $138.33B | 0.00% | 20.91% | 23.54% | 10.35% | 5.97% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 714.72M | 544.13M | 578.16M | 651.63M | 640.80M | 752.16M | 784.53M | 870.11M | 858.43M | 941.29M | 949.83M | 1.41B | 1.52B | 1.52B | 1.54B | 1.63B | 1.72B | 1.79B | 1.98B | 2.10B | 2.20B | 2.33B | 2.37B | 2.49B | 2.48B | 2.69B | 2.65B | 2.77B | - | 2.77B | 2.96B | 3.08B | 3.19B | 2.99B | 3.33B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 363.00M | 407.50M | 414.80M | 466.00M | 392.80M | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.41B | 2.56B | 2.66B | 2.72B | 2.59B | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.38B | 1.40B | 1.42B | 1.59B | 1.46B | - |
| Operating Income | -53.70M | -14.33M | 3.35M | -18.73M | 39.64M | 270.84M | 52.71M | -326.04M | 125.74M | 128.90M | 172.88M | 205.65M | 127.72M | 276.81M | 269.96M | 99.33M | 551.47M | 720.22M | 718.03M | 672.24M | 745.79M | 887.80M | -37.90M | 1.05B | 1.04B | 1.11B | 1.13B | 779.00M | 1.03B | 1.04B | 1.14B | -3.51B | 1.12B | - | 1.03B | 1.15B | 1.24B | 1.13B | 1.14B | 1.25B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.08B | 1.34B | 1.36B | 1.39B | 1.19B | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.80M | 3.00M | 3.70M | 3.30M | 3.30M | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 730.40M | 1.28B | 1.30B | 1.33B | 1.25B | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 84.10M | 250.10M | 215.90M | 139.90M | 221.50M | - |
| Net Income | -73.73M | -41.63M | -64.53M | -38.84M | 32.95M | 247.76M | 18.00M | -102.95M | 100.68M | 210.26M | 207.36M | 128.75M | 1.55B | 268.63M | 267.43M | 57.52M | 583.23M | 602.75M | 837.27M | 667.43M | 604.19M | 653.10M | 67.00M | 851.90M | 762.10M | 810.50M | 930.50M | 699.80M | 915.70M | 1.04B | 1.10B | -3.59B | 1.05B | - | 646.30M | 1.03B | 1.08B | 1.19B | 1.03B | 1.10B |
| Diluted EPS | - | -0.17 | -0.26 | -0.16 | 0.13 | 0.99 | 0.07 | -0.41 | 0.39 | 0.81 | 0.80 | 0.50 | 5.97 | 1.03 | 1.03 | 0.22 | 2.23 | 2.29 | 3.18 | 2.53 | 2.30 | 2.49 | 0.26 | 3.28 | 2.96 | 3.13 | 3.59 | 2.69 | 3.52 | 3.97 | 4.21 | -13.92 | 4.01 | - | 2.49 | 3.99 | 4.20 | 4.65 | 4.02 | 4.31 |
| R&D Expense | 310.18M | 255.86M | 271.01M | 272.37M | 248.45M | 273.56M | 289.45M | 454.95M | 306.66M | 310.55M | 337.53M | 330.51M | 437.88M | 339.49M | 379.09M | 555.95M | 480.01M | 448.53M | 420.93M | 493.50M | 466.58M | 456.00M | 1.41B | 493.75M | 603.10M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 175.50M | 101.89M | 143.37M | 1.41B | 1.53B | 1.21B | 580.41M | 1.03B | 1.70B | 2.49B | 3.05B | 4.16B | 6.21B | - | 8.93B | 9.87B | 11.02B | 12.00B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.08B | 1.26B | 1.53B | 1.65B |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.85B | 8.61B | 9.49B | 10.35B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.60B | 4.83B | 9.72B | 5.80B |
| Operating Income | -462.71M | -614.01M | -696.08M | 113.82M | 46.73M | -610.01M | -692.41M | -466.88M | 9.94M | 123.24M | 635.15M | 1.20B | 2.86B | - | 4.25B | 3.78B | -233.40M | 4.55B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.44B | 4.61B | 486.30M | 4.87B |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 54.80M | 44.10M | 30.60M | 13.30M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.23B | 4.38B | 248.50M | 4.64B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 910.40M | 760.20M | 784.10M | 690.00M |
| Net Income | - | -642.18M | -754.63M | 29.57M | -107.03M | -445.03M | -738.55M | -556.33M | -112.05M | 263.48M | 2.10B | 1.18B | 2.71B | - | 3.32B | 3.62B | -535.60M | 3.95B |
| Diluted EPS | -3.27 | -3.71 | -3.77 | 0.14 | -0.50 | -1.98 | -3.14 | -2.31 | -0.46 | 1.04 | 8.09 | 4.51 | 10.29 | - | 12.82 | 13.89 | -2.08 | 15.32 |
| R&D Expense | 516.91M | 550.27M | 637.42M | 707.71M | 765.90M | 882.10M | 855.51M | 995.92M | 1.05B | 1.32B | 1.42B | 1.75B | 1.83B | 3.05B | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Jan 2018 | Dec 2018 | Jan 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.96B | 1.73B | 2.20B | 2.76B | 2.32B | 2.33B | 2.50B | 2.90B | 3.55B | 3.56B | 6.25B | 6.26B | 8.32B | 11.75B | 13.43B | 18.15B | 22.73B | 22.53B | 25.64B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.23B | 14.14B | 9.60B | 11.20B |
| Cash & Equivalents | 355.66M | 389.12M | 446.66M | 243.20M | 475.32M | 489.41M | 569.30M | 625.26M | 714.77M | 1.18B | 1.67B | - | 2.65B | - | 3.11B | 5.99B | 6.79B | 10.50B | 10.37B | 4.57B | 5.08B |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 460.60M | 738.80M | 1.21B | 1.69B |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.44B | 1.56B | 1.61B | 2.05B |
| Total Liabilities | - | - | 859.14M | 1.22B | 1.24B | 1.52B | 962.64M | 1.24B | 1.40B | 1.56B | 1.50B | - | 1.81B | - | 2.23B | 3.06B | 3.33B | 4.24B | 5.15B | 6.12B | 6.98B |
| Current Liabilities | - | - | 284.88M | 474.78M | 392.35M | 432.62M | 397.83M | 368.25M | 506.17M | 792.54M | 807.26M | - | 1.12B | - | 1.33B | 1.88B | 2.14B | 2.74B | 3.55B | 3.56B | 3.86B |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 899.70M | 808.40M | 1.74B | 2.03B |
| Total Equity | 271.30M | 238.87M | 1.10B | 503.97M | 786.84M | 999.18M | 1.36B | 1.08B | 939.97M | 1.16B | 2.03B | - | 4.44B | - | 6.09B | 8.69B | 10.10B | 13.91B | 17.58B | 16.41B | 18.67B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 257.01M | 257.70M | 256.94M | 253.99M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -226.48M | -427.59M | -635.44M | 143.74M | 267.84M | -60.67M | -573.11M | -365.43M | 236.10M | 844.94M | 1.27B | 1.57B | 3.25B | - | 4.13B | 3.54B | -492.60M | 3.63B |
| Investing Cash Flow | -360.65M | -508.73M | 7.30M | - | - | - | - | 268.86M | 51.24M | -483.33M | -202.16M | -1.24B | 99.40M | - | -321.10M | -3.14B | -3.77B | -945.40M |
| Financing Cash Flow | 620.74M | 999.01M | 425.06M | - | - | - | - | 188.92M | 133.27M | 68.40M | -71.22M | 126.80M | -505.30M | - | -67.70M | -562.20M | -1.49B | -2.26B |
| Capital Expenditure | -32.18M | -23.50M | -38.05M | -34.59M | -71.14M | -51.39M | -51.20M | -45.30M | -56.56M | -99.42M | -95.45M | -75.40M | -259.80M | - | -204.70M | -258.40M | -485.40M | -437.60M |
| Free Cash Flow | -258.66M | -451.08M | -673.50M | 109.14M | 196.70M | -112.06M | -624.31M | -410.73M | 179.54M | 745.52M | 1.17B | 1.49B | 2.99B | - | 3.93B | 3.28B | -978.00M | 3.19B |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.74B | -166.60M | -5.76B | 424.70M |
| Share Buybacks | - | - | - | - | - | - | - | - | 0 | 0 | 350.04M | 186.00M | 539.10M | 1.43B | 0 | 427.60M | 1.18B | 2.02B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 87.9% | 87.2% | 86.1% | 86.2% |
| Operating Margin % | -263.6% | -602.6% | -485.5% | 8.1% | 3.1% | -50.3% | -119.3% | -45.2% | 0.6% | 5.0% | 20.8% | 28.8% | 46.0% | - | 47.6% | 38.3% | -2.1% | 37.9% |
| Net Margin % | - | -630.3% | -526.3% | 2.1% | -7.0% | -36.7% | -127.2% | -53.9% | -6.6% | 10.6% | 68.8% | 28.3% | 43.7% | - | 37.2% | 36.7% | -4.9% | 32.9% |
| ROE % | - | -58.6% | -149.7% | 3.8% | -10.7% | -32.8% | -68.7% | -59.2% | -9.7% | 13.0% | 47.3% | 19.3% | 31.2% | - | 23.9% | 20.6% | -3.3% | 21.2% |
| ROCE % | - | -36.8% | -55.7% | 6.3% | 2.0% | -31.8% | -35.2% | -23.4% | 0.5% | 4.5% | 12.4% | 17.1% | 28.9% | - | 27.6% | 19.7% | -1.2% | 20.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Capital World Investors | 10.29% | 26.12M | $14.15B |
| 2 | Blackrock Inc. | 9.50% | 24.11M | $13.06B |
| 3 | Capital Research Global Investors | 7.68% | 19.49M | $10.56B |
| 4 | Vanguard Capital Management LLC | 6.53% | 16.58M | $8.98B |
| 5 | State Street Corporation | 4.68% | 11.87M | $6.43B |
| 6 | Invesco Ltd. | 3.17% | 8.04M | $4.36B |
| 7 | JPMORGAN CHASE & CO | 2.57% | 6.52M | $3.53B |
| 8 | Geode Capital Management, LLC | 2.37% | 6.02M | $3.26B |
| 9 | Vanguard Portfolio Management LLC | 1.92% | 4.88M | $2.64B |
| 10 | Capital International Investors | 1.85% | 4.70M | $2.54B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VRTX
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
They could both outperform the market over the medium term, but one appears to have a clear edge.
How Is Vertex Pharmaceuticals' Stock Performance Compared to Other Biotech Stocks?
Vertex Pharmaceuticals has underperformed the Biotech industry over the past year, but analysts are moderately optimistic about the stock’s prospects.
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Vertex (VRTX) Stock Trades At A Premium On Earnings Yet Looks Fair On Broader Checks
Vertex Pharmaceuticals stock has delivered strong multi year gains, and current valuation checks suggest the shares now look closer to fairly priced than clearly cheap or clearly expensive. Vertex Pharmaceuticals has returned 184.9% over th…
Goldman Sachs refreshes conviction lists on both sides of the Atlantic
Investing.com -- Goldman Sachs updated its U.S. and European conviction lists for September, adding several new names as it refreshed its highest-conviction ideas heading into the autumn.
Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform
The completed acquisition adds PALSONIFY and atumelnant to Vertex’s portfolio, with the two therapies carrying combined peak annual revenue potential of more than $5 billion according to the company. Key Investor TakeawaysVertex Pharmaceuti…
VRTX — Frequently Asked Questions
What is the current share price of Vertex Pharmaceuticals Incorporated (VRTX)?
As of 2026-09-07 16:24 PDT, Vertex Pharmaceuticals Incorporated (VRTX) trades at $546.12 on NasdaqGS. Its 52-week range is $376.62 to $557.96.
What is the market capitalisation of VRTX?
Vertex Pharmaceuticals Incorporated (VRTX) has a market capitalisation of $138.33B on NasdaqGS.
What is the P/E ratio of VRTX?
VRTX trades at a trailing price-to-earnings (P/E) ratio of 31.79. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 6.21.
What is the return on equity (ROE) of VRTX?
VRTX has a return on equity (ROE) of 23.54%. Its return on capital employed (ROCE) is 20.91%.
Is VRTX a good stock to buy?
This page provides a data-driven analysis of Vertex Pharmaceuticals Incorporated (VRTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.